Spots Global Cancer Trial Database for recurrent adult hodgkin lymphoma
Every month we try and update this database with for recurrent adult hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00090909 | Lymphoma | cisplatin dexamethasone gemcitabine hyd... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | NCT00907036 | Lymphoma | alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | NCT01476839 | Recurrent Adult... | basiliximab carmustine etoposide cytarabine melphalan pharmacological... laboratory biom... autologous hema... yttrium Y 90-la... | 18 Years - 70 Years | City of Hope Medical Center | |
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | NCT00003056 | Leukemia Lymphoma Graft Versus Ho... | cyclosporine cyclosporine an... | 18 Years - 55 Years | Takeda | |
| Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00262860 | Lymphoma | bortezomib gemcitabine hyd... | 18 Years - 120 Years | University of Rochester | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation | NCT00003143 | Lymphoma | Amifostine DHAP | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment | NCT00881387 | Lymphoma | rituximab gemcitabine hyd... vinorelbine dit... | 18 Years - 120 Years | University of Miami | |
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | NCT00052442 | Lymphoma | pralatrexate | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | NCT00101244 | Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | ispinesib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT01460940 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Recurrent Adult... | panobinostat lenalidomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease | NCT00005595 | Lymphoma | arsenic trioxid... | 16 Years - | Northwestern University | |
| Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma | NCT00255723 | Lymphoma | carboplatin etoposide ifosfamide | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation | NCT00003143 | Lymphoma | Amifostine DHAP | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma | NCT01165645 | Hodgkin Lymphom... Stage I Adult H... Stage II Adult ... Stage III Adult... Stage IV Adult ... | lopinavir ritonavir polymerase chai... flow cytometry enzyme-linked i... laboratory biom... | 18 Years - | Mayo Clinic | |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | NCT00027820 | Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child... | Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M... | - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00002522 | Lymphoma | cisplatin cyclophosphamid... etoposide autologous bone... bone marrow abl... peripheral bloo... syngeneic bone ... radiation thera... | 15 Years - 70 Years | Temple University | |
| Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | NCT00132028 | Adult Favorable... Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Adult Unfavorab... Recurrent Adult... | vorinostat laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma | NCT00025636 | Lymphoma | filgrastim carmustine cisplatin cyclophosphamid... cytarabine dexamethasone etoposide melphalan methotrexate vincristine sul... bone marrow abl... peripheral bloo... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | NCT00117988 | Anaplastic Larg... Recurrent Adult... Recurrent Mantl... | tanespimycin | 16 Years - | National Cancer Institute (NCI) | |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | NCT02240719 | Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Refractory Chro... Multiple Myelom... | everolimus bendamustine hy... | 18 Years - | University of California, Davis | |
| Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma | NCT00265889 | Lymphoma | filgrastim busulfan cyclophosphamid... etoposide melphalan autologous-auto... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease | NCT00005595 | Lymphoma | arsenic trioxid... | 16 Years - | Northwestern University | |
| Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma | NCT00389506 | Lymphoma | LMB-2 immunotox... cyclophosphamid... fludarabine pho... pharmacological... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | NCT01008462 | B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac... | Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma | NCT00055783 | Lymphoma | apolizumab | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma | NCT00134082 | Lymphoma | KGEL vaccine Filgrastim Rituximab Cyclophosphamid... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma | NCT01412307 | Recurrent Adult... | Lenalidomide Bendamustine Bio-specimen Re... | 18 Years - | GiovanniPascale | |
| Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00908180 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cyclosporine cytarabine etoposide melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease | NCT00003936 | Lymphoma | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00337194 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular S... Recurrent Adult... | monoclonal anti... placebo vinorelbine tar... pegylated lipos... gemcitabine hyd... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease | NCT00003936 | Lymphoma | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00005613 | Lymphoma | cyclophosphamid... etoposide BCNU | 15 Years - 55 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | NCT00006220 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | arsenic trioxid... tretinoin | 15 Years - | Washington University School of Medicine | |
| Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00003849 | Lymphoma | rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT01780662 | Recurrent Adult... Recurrent Child... Refractory Chil... | Brentuximab Ved... Gemcitabine Hyd... | 13 Months - 30 Years | National Cancer Institute (NCI) | |
| S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma | NCT00121186 | Lymphoma | fludarabine pho... melphalan methotrexate tacrolimus allogeneic bone... peripheral bloo... | 18 Years - | SWOG Cancer Research Network | |
| Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00005998 | Lymphoma | carmustine cyclophosphamid... cytarabine dexamethasone etoposide filgrastim mitoxantrone hy... retrovirus vect... in vitro-treate... peripheral bloo... radiation thera... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00086840 | Recurrent Adult... Recurrent Adult... Refractory Chro... | temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | NCT00093704 | Lymphoma Lymphoprolifera... | bortezomib + ga... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00086840 | Recurrent Adult... Recurrent Adult... Refractory Chro... | temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | NCT00005803 | Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph... | Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | NCT02797470 | HIV Infection Mature T-Cell a... Plasmablastic L... Recurrent Adult... Recurrent Adult... Recurrent Burki... Recurrent Folli... Stage III Folli... Stage III Mantl... Stage IV Follic... Stage IV Mantle... | Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Lentivirus Vect... Melphalan Peripheral Bloo... | 18 Years - | AIDS Malignancy Consortium | |
| Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer | NCT00005993 | Breast Cancer Lymphoma | aldesleukin filgrastim recombinant hum... peripheral bloo... | 18 Years - 65 Years | Masonic Cancer Center, University of Minnesota | |
| Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | NCT01076543 | AIDS-Related Ho... Recurrent Adult... Recurrent Folli... Recurrent Lymph... Recurrent Margi... Recurrent Non-H... Recurrent T-Cel... Waldenstrom Mac... | Laboratory Biom... Lenalidomide Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders | NCT00304005 | Leukemia Lymphoma | laromustine | 18 Years - | National Cancer Institute (NCI) | |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | NCT00101244 | Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | ispinesib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00086840 | Recurrent Adult... Recurrent Adult... Refractory Chro... | temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00002522 | Lymphoma | cisplatin cyclophosphamid... etoposide autologous bone... bone marrow abl... peripheral bloo... syngeneic bone ... radiation thera... | 15 Years - 70 Years | Temple University | |
| Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma | NCT00002552 | Lymphoma Multiple Myelom... | filgrastim sargramostim carmustine cyclophosphamid... cytarabine etoposide leucovorin calc... methotrexate perfosfamide therapeutic hyd... allogeneic bone... autologous bone... in vitro-treate... peripheral bloo... syngeneic bone ... radiation thera... | - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00003849 | Lymphoma | rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma | NCT00265889 | Lymphoma | filgrastim busulfan cyclophosphamid... etoposide melphalan autologous-auto... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00908180 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cyclosporine cytarabine etoposide melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | NCT00093704 | Lymphoma Lymphoprolifera... | bortezomib + ga... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma | NCT00006100 | Lymphoma | aldesleukin allogeneic Epst... fludarabine pho... peripheral bloo... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | NCT00060372 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Atypical Chroni... Childhood Myelo... Chronic Myeloge... Disseminated Ne... Malignant Neopl... Ovarian Chorioc... Ovarian Embryon... Ovarian Immatur... Ovarian Mature ... Ovarian Mixed G... Ovarian Monoder... Ovarian Polyemb... Ovarian Yolk Sa... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Malig... Recurrent Mantl... Recurrent Neuro... Recurrent Ovari... Recurrent Ovari... Refractory Chro... Refractory Mult... Relapsing Chron... Stage I Multipl... Stage II Multip... Stage II Ovaria... Stage III Malig... Stage III Multi... Stage III Ovari... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Ovaria... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Tera... Testicular Yolk... Testicular Yolk... Testicular Yolk... | ipilimumab therapeutic all... | 18 Years - | National Cancer Institute (NCI) | |
| Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | NCT00004132 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera... | 12 Years - 65 Years | National Cancer Institute (NCI) | |
| S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma | NCT00121186 | Lymphoma | fludarabine pho... melphalan methotrexate tacrolimus allogeneic bone... peripheral bloo... | 18 Years - | SWOG Cancer Research Network | |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | NCT00005803 | Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph... | Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT01535924 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Recurrent Adult... | gemcitabine hyd... bendamustine hy... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies | NCT00002818 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... | cytarabine deoxycytidine | 18 Years - 120 Years | Virginia Commonwealth University | |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | NCT00006368 | Brain and Centr... Breast Cancer Gastrointestina... Islet Cell Tumo... Lung Cancer Lymphoma Melanoma (Skin) Neoplastic Synd... | yttrium Y 90-ed... | 18 Years - | Novartis | |
| Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | NCT00093704 | Lymphoma Lymphoprolifera... | bortezomib + ga... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma | NCT00003741 | Lymphoma | monoclonal anti... | 18 Years - | National Cancer Institute (NCI) | |
| PS-341 in Treating Patients With Hematologic Cancer | NCT00006098 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | bortezomib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | NCT02240719 | Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Refractory Chro... Multiple Myelom... | everolimus bendamustine hy... | 18 Years - | University of California, Davis | |
| Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment | NCT00014209 | Lymphoma | cisplatin dexamethasone gemcitabine hyd... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma | NCT00389506 | Lymphoma | LMB-2 immunotox... cyclophosphamid... fludarabine pho... pharmacological... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00005613 | Lymphoma | cyclophosphamid... etoposide BCNU | 15 Years - 55 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma | NCT00025636 | Lymphoma | filgrastim carmustine cisplatin cyclophosphamid... cytarabine dexamethasone etoposide melphalan methotrexate vincristine sul... bone marrow abl... peripheral bloo... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | NCT00006373 | Lymphoma | etoposide ifosfamide topotecan hydro... autologous bone... Mesna | 18 Years - 64 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT01460940 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Recurrent Adult... | panobinostat lenalidomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers | NCT00619645 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... peripheral bloo... | 18 Years - 120 Years | University of California, Davis | |
| VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders | NCT00304005 | Leukemia Lymphoma | laromustine | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
